Eurostars VALBIOME
Lead Participant:
CLINICAGENO LIMITED
Abstract
The success rate of IVF-ET therapy (20-25%) is still disappointing for couples and their caregivers. Evidence has accumulated showing that disturbances in the vaginal microbiota are an important and actionable biomarker for successful IVF-ET therapy. The VALBIOME project will develop an easy-to-use assay that enables physicians to assess and monitor the vaginal microbial status during IVF-ET therapy.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
Participant |
||
| CLINICAGENO LIMITED |
People |
ORCID iD |